Mostrando 7 resultados de: 7
Subtipo de publicación
Article(7)
Publisher
New England Journal of Medicine(3)
Circulation(2)
Journal of the American College of Cardiology(1)
The Lancet Diabetes and Endocrinology(1)
Cardiovascular efficacy and safety of bococizumab in high-risk patients
ArticleAbstract: BACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilPalabras claves:Autores:Abbott J.D., Amarenco P., Anderson P., Baultrukonis D., Black H., Blake G., Borer J.S., Brunell R., Buonanno M., Carmena R., Chakrabarti A., Chaudhuri S., Chun H., Civeira F., Colquhoun D., Conde D., Cortada J.B., Curto M., Dan G.A., Dearborn-Tomazos J., Edes I., Epsley C., Evans B., Flather M., Foody J., Frederich R., Frolova M., Furie K.L., Gao R., Gelfand E., Glynn R.J., Goetsch M., Grégoire J., Grobbee D., Hessinger D., Hwang J.J., Jacoby D., Jadbabaie F., Jensen H.K., Johnson M., Jukema J.W., Kahan T., Karpov Y., Kastelein J.J.P., Koenig W., Lee C.W., Leiva Pons J.L., Lorenzatti A.J., Lotan C., Maggioni A.P., Manga P., Masiukiewicz U., McCullough L., McMurray J.J.V., McNamara R., McPherson C., Mellbin L., Miller M., Missault L., Montalescot G., Mosterd A., Mridha K., Murin J., Neaton J., Nicolau J.C., Nissen S.E., Noble S., O’Neill B., Piazza G., Pinto D., Ponikowski P., Powell C., Pride Y., Revkin J., Ridker P.M., Sandra Verónica Falconí Peláez, Sansing L.H., Santos R.D., Savolainen M., Savonitto S., Schiele F.N., Schindler J., Schwartz P.F., Shear C.L., Silverman I.E., Solar M., Soran H., Sritara P., Tarasenko L., Tardif J.C., Tökgozoğlu L., Urina M., Vrablik M., Wang E., Wei C., Welty F., White H.D., Wright R.S., Yunis C., Zannad F.Fuentes:googlescopusApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
ArticleAbstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoBPalabras claves:acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitorsAutores:Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.Fuentes:scopusAlirocumab and cardiovascular outcomes after acute coronary syndrome
ArticleAbstract: BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemicPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Ducrocq G., Eapen Z., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Quintero K., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valdovinos P.C.M., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:scopusEzetimibe added to statin therapy after acute coronary syndromes
ArticleAbstract: BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk ofPalabras claves:Autores:Armstrong P., Aylward P.E., Azize G., Ballantyne C., Bassand J., Beloscar J., Beltrano M., Berra F., Blazing M.A., Bluguermann J., Blumberg E., Bohula E.A., Bono J., Brady A.J.B., Braunwald E., Britto F., Califf R.M., Cannon C.P., Carlessi C., Carlevaro O., Carrageta M., CARTASEGNA L.U.I.S., Caruso O., Casalins M., Castoldi M., Centeno E., Cocco N., Colombo H., Corbalan R., Dalby A.J., Darius H., De Ferrari G.M., de Lemos J., De Lucca P., Dellatorre M., Dellborg M., Duris T., Duronto E., Egido J., Fanuele M., Farnier M., Fernandez H., Fernández R.O., Genest J., Giugliano R.P., Grande P., Guerrero R., Guneri S., Gurfinkel E., HOMINAL M.A., Im K.A., Isaza D., Jukema J.W., Keltai M., Kesaniemi A., Kleiman N.S., Lewis B.S., López-Sendón J.L., Lozada A.F., Mach F., MACIN S.M., Maffeo H., Mathur A., Maurer G., Mauro D., McCagg A., McGuire D., Milesi R., Mittal S., Musliner T.A., NANI S., Nicolau J.C., Ophuis T.O., Parkhomenko A.N., Pedersen T., Procopio G., Ramos H., Reddy K., Reges P., Reist C., Ricart J., Ruiz N., Ruzyllo W., Schmuck R., Seung K., Spinar J., Terns P., Tershakovec A.M., Theroux P., Tonkin A.M., Turri D., Van de Werf F., Viso M., Voitk J., White H.D., White J.A., Wiviott S.D., Yan Duarte, Zarandon R.Fuentes:scopusEffects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
ArticleAbstract: Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovasculPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Colhoun H.M., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., DIaz R., Dilic M., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Loizeau V., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
ArticleAbstract: Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for mPalabras claves:acute coronary syndrome, lipoprotein(a), low-density lipoprotein cholesterol, PCSK9 inhibitorAutores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Scemama M., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusRisk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
ArticleAbstract: Background: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapPalabras claves:acute coronary syndrome, alirocumab, dyslipidemias, GUIDELINEAutores:Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., DIaz R., Goodman S.G., Harrington R.A., Jukema J.W., Li Q.H., Lopes R.D., Louie M.J., Moriarty P.M., PATRICIO LOPEZ -JARAMILLO, Roe M.T., Schwartz G.G., Steg P.G., Szarek M., Vogel R., White H.D., Zeiher A.M.Fuentes:googlescopus